Claret Asset Management Corp Takes $9.30 Million Position in Indivior PLC (NASDAQ:INDV)

Claret Asset Management Corp acquired a new stake in Indivior PLC (NASDAQ:INDV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 748,486 shares of the company's stock, valued at approximately $9,304,000. Indivior makes up about 1.5% of Claret Asset Management Corp's holdings, making the stock its 18th biggest position. Claret Asset Management Corp owned 0.54% of Indivior as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Indivior in the fourth quarter worth $56,000. Stifel Financial Corp acquired a new position in Indivior during the 3rd quarter worth $100,000. Jane Street Group LLC acquired a new position in Indivior during the 3rd quarter worth $180,000. Rathbones Group PLC increased its holdings in Indivior by 11.6% during the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock worth $183,000 after purchasing an additional 1,483 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new stake in Indivior in the 3rd quarter valued at about $294,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Stock Up 11.1 %

INDV traded up $1.05 on Thursday, reaching $10.50. The company's stock had a trading volume of 619,510 shares, compared to its average volume of 956,654. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -30.16 and a beta of 0.93. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $19.13. The stock has a 50 day moving average of $9.45 and a two-hundred day moving average of $10.30.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. As a group, analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on INDV shares. RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Piper Sandler dropped their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. Finally, Rodman & Renshaw assumed coverage on shares of Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price objective on the stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.